Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026)
Compugen (CGEN) reported Total Non-Current Liabilities of $28.5 million for Q1 2026, down 23.76% on a YoY basis from $37.3 million in Q1 2025, and down 8.95% sequentially from $31.3 million in Q4 2025.
Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Compugen (CGEN) has 18 years of Total Non-Current Liabilities data on file, last reported at $28.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 23.76% year-over-year to $28.5 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (down 23.76% YoY), and the FY2025 full-year result was $31.3 million, down 21.67% from the prior year.
- Total Non-Current Liabilities slipped to $28.5 million in Q1 2026, from $31.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $39.9 million in Q4 2024 to a low of $4.0 million in Q3 2023.
- A 5-year average of $21.3 million and a median of $28.5 million in 2026 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 45.34% in 2022 and surged 779.92% in 2024, its largest moves.
- Tracing CGEN's Total Non-Current Liabilities over 5 years: stood at $4.6 million in 2022, then soared by 544.72% to $29.5 million in 2023, then surged by 35.28% to $39.9 million in 2024, then retreated by 21.67% to $31.3 million in 2025, then fell by 8.95% to $28.5 million in 2026.
- Business Quant data shows CGEN's Total Non-Current Liabilities at $28.5 million in Q1 2026, $31.3 million in Q4 2025, and $33.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | 28.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47 Mn |
| Dec 31, 2025 | 31.27 Mn |
| Sep 30, 2025 | 33.74 Mn |
| Jun 30, 2025 | 35.69 Mn |
| Mar 31, 2025 | 37.34 Mn |
| Dec 31, 2024 | 39.92 Mn |
| Sep 30, 2024 | 35.27 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Mar 31, 2024 | 29.40 Mn |
| Dec 31, 2023 | 29.51 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.58 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 7.08 Mn |
| Dec 31, 2021 | 8.37 Mn |
| Sep 30, 2021 | 7.22 Mn |
| Jun 30, 2021 | 7.55 Mn |